Pfizer (PFE) Stock Value Rose While Guyasuta Investment Advisors Has Lowered Its Stake; West Oak Capital Increased Its Chevrontexaco (CVX) Position by $17.36 Million; Market Valuation Rose

Pfizer Inc. (NYSE:PFE) Logo

Guyasuta Investment Advisors Inc decreased its stake in Pfizer Inc (PFE) by 2.1% based on its latest 2018Q3 regulatory filing with the SEC. Guyasuta Investment Advisors Inc sold 16,745 shares as the company’s stock rose 5.56% while stock markets declined. The institutional investor held 781,132 shares of the health care company at the end of 2018Q3, valued at $34.42 million, down from 797,877 at the end of the previous reported quarter. Guyasuta Investment Advisors Inc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $244.57 billion market cap company. The stock decreased 2.38% or $1.03 during the last trading session, reaching $42.31. About 37.63M shares traded or 48.90% up from the average. Pfizer Inc. (NYSE:PFE) has risen 25.07% since January 10, 2018 and is uptrending. It has outperformed by 25.07% the S&P500. Some Historical PFE News: 17/05/2018 – INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer; 29/03/2018 – PFIZER INC – PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED; 20/04/2018 – P&G’s vitamin boost could signal more to come; 07/05/2018 – Pfizer at Deutsche Bank Health Care Conference Tomorrow; 07/03/2018 – Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference; 07/03/2018 – Pfizer breaks off a 5-year, $635M collaboration deal with CytomX, with nothing to show for it $PFE $CTMX; 24/05/2018 – AUSTRALIAN COURT ORDERS ACCC APPEAL VS PFIZER BE DISMISSED; 15/05/2018 – REXAHN PHARMACEUTICALS INC – SMC HAS CONFIRMED THAT COMBINATION OF RX-3117 AND ABRAXANE IS SAFE AND WELL TOLERATED; 09/04/2018 – HOFFMANN-LA ROCHE SAYS TECENTRIQ APPROVED BY HEALTH CANADA; 16/05/2018 – NOVARTIS AG NOVN.S CEO SAYS CONTINUES TO BELIEVE KISQUALI IMPORTANT BUT NOT AS LARGE AS ONCE THOUGHT

West Oak Capital Llc increased its stake in Chevrontexaco Corp (CVX) by 0.71% based on its latest 2018Q3 regulatory filing with the SEC. West Oak Capital Llc bought 142 shares as the company’s stock rose 0.40% while stock markets declined. The institutional investor held 20,046 shares of the integrated oil company at the end of 2018Q3, valued at $2.45B, up from 19,904 at the end of the previous reported quarter. West Oak Capital Llc who had been investing in Chevrontexaco Corp for a number of months, seems to be bullish on the $216.78 billion market cap company. The stock increased 0.16% or $0.18 during the last trading session, reaching $113.45. About 6.02 million shares traded. Chevron Corporation (NYSE:CVX) has declined 3.92% since January 10, 2018 and is downtrending. It has underperformed by 3.92% the S&P500. Some Historical CVX News: 28/03/2018 – Chevron Announces New First Source Lubrication Marketer Lube; 06/03/2018 – Chevron: Advancing Development of Unconventional Resources, Particularly in U.S. Permian Basin; 27/04/2018 – CHEVRON CORP CVX.N FIRST-QUARTER EARNINGS CONFERENCE CALL BEGINS; CHIEF EXECUTIVE MIKE WIRTH NOT ON CALL; 23/03/2018 – Cal EMA Spills: SPILL Report – Chevron – 03/23/2018 04:06 PM; 06/03/2018 – Chevron: Focusing on Cutting Costs, Delivering Production Growth From Gorgon and Wheatstone LNG Projects in Australia; 21/05/2018 – GLENCORE IS SAID TO NEAR $1B CHEVRON SOUTHERN AFRICA DEAL; 24/05/2018 – Sea-Land Chemical Company and Chevron Phillips Chemical Company LP Expand Distribution Relationship to Include Normal Alpha; 30/05/2018 – CHEVRON – ABOUT 92 PCT OF VOTES CAST WERE VOTED AGAINST STOCKHOLDER PROPOSAL REGARDING REPORT ON TRANSITION TO LOW CARBON BUSINESS MODEL; 03/05/2018 – CHEVRON FILES DEBT SECURITIES SHELF; 28/05/2018 – Chevron restores production on Gulf of Mexico platforms after storm

Investors sentiment increased to 1.05 in Q3 2018. Its up 0.02, from 1.03 in 2018Q2. It increased, as 49 investors sold CVX shares while 648 reduced holdings. 121 funds opened positions while 611 raised stakes. 1.18 billion shares or 1.47% less from 1.19 billion shares in 2018Q2 were reported. 18,180 were accumulated by Virtu Financial Ltd Liability Corp. Woodmont Inv Counsel Ltd Company has invested 1.03% of its portfolio in Chevron Corporation (NYSE:CVX). 4,014 are owned by Weatherstone Mgmt. Bancshares Of Mellon Corporation stated it has 0.67% in Chevron Corporation (NYSE:CVX). Stralem And Communications holds 2.04% of its portfolio in Chevron Corporation (NYSE:CVX) for 56,175 shares. Roundview Cap Ltd owns 0.65% invested in Chevron Corporation (NYSE:CVX) for 21,518 shares. Waters Parkerson & accumulated 2.51% or 251,119 shares. Hennessy Advsr invested in 92,405 shares or 0.42% of the stock. Horizon Kinetics Limited Company reported 0.04% stake. Roanoke Asset Mgmt Ny reported 4,430 shares stake. Artemis Invest Management Ltd Liability Partnership invested in 25,450 shares. Rockland Trust Comm stated it has 2.44% of its portfolio in Chevron Corporation (NYSE:CVX). Parkside Bank Tru has 7,113 shares. Bkd Wealth Advsrs Limited Liability Corp holds 31,061 shares. Elm Advisors Lc owns 8,200 shares.

West Oak Capital Llc, which manages about $281.18M and $173.03B US Long portfolio, decreased its stake in Mc Donalds Corp (NYSE:MCD) by 450 shares to 1,650 shares, valued at $276.03M in 2018Q3, according to the filing. It also reduced its holding in Procter & Gamble Co (NYSE:PG) by 100 shares in the quarter, leaving it with 19,791 shares, and cut its stake in Interpublic Group Of Cos (NYSE:IPG).

Since September 13, 2018, it had 0 buys, and 4 insider sales for $2.82 million activity.

Among 37 analysts covering Chevron Corporation (NYSE:CVX), 28 have Buy rating, 0 Sell and 9 Hold. Therefore 76% are positive. Chevron Corporation had 132 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Friday, October 27 by RBC Capital Markets. The firm has “Buy” rating by Piper Jaffray given on Thursday, August 24. As per Wednesday, January 4, the company rating was upgraded by Bank of America. Barclays Capital maintained the stock with “Overweight” rating in Monday, April 30 report. The firm earned “Sector Perform” rating on Friday, February 9 by RBC Capital Markets. As per Thursday, January 11, the company rating was upgraded by BMO Capital Markets. PiperJaffray upgraded Chevron Corporation (NYSE:CVX) on Tuesday, August 9 to “Overweight” rating. As per Thursday, December 21, the company rating was maintained by Scotia Capital. The rating was maintained by JP Morgan on Tuesday, December 15 with “Overweight”. Goldman Sachs upgraded the shares of CVX in report on Monday, October 31 to “Buy” rating.

Investors sentiment increased to 0.85 in 2018 Q3. Its up 0.07, from 0.78 in 2018Q2. It is positive, as 41 investors sold PFE shares while 741 reduced holdings. 142 funds opened positions while 520 raised stakes. 3.96 billion shares or 0.44% less from 3.98 billion shares in 2018Q2 were reported. Cap Of America Inc holds 0.07% or 11,179 shares. Azimuth Capital Mgmt Ltd invested 1.68% in Pfizer Inc. (NYSE:PFE). Waters Parkerson Communications Limited Liability Company has 408,768 shares for 1.47% of their portfolio. Macguire Cheswick And Tuttle Invest Counsel Llc accumulated 4,810 shares. Family Firm reported 0.1% of its portfolio in Pfizer Inc. (NYSE:PFE). Viking Fund Management Limited Liability Company has invested 0.64% in Pfizer Inc. (NYSE:PFE). M Kraus & has 20,384 shares for 0.52% of their portfolio. Sunbelt Securities Inc accumulated 56,736 shares. Bbva Compass Bank Incorporated has invested 0.88% in Pfizer Inc. (NYSE:PFE). Birinyi Assoc reported 0.29% stake. Ar Asset Incorporated reported 124,472 shares or 2.02% of all its holdings. Hall Laurie J Trustee has 37,389 shares. Evercore Wealth Limited Liability holds 342,239 shares or 0.48% of its portfolio. Perkins Coie Tru holds 1.19% or 58,291 shares in its portfolio. 4.17 million were accumulated by Natixis.

Among 23 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 14 Hold. Therefore 35% are positive. Pfizer had 89 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Friday, August 28 report. As per Thursday, April 7, the company rating was reinitiated by JP Morgan. The stock has “Buy” rating by Piper Jaffray on Tuesday, October 31. On Monday, June 20 the stock rating was maintained by Jefferies with “Buy”. BMO Capital Markets maintained the stock with “Buy” rating in Tuesday, September 5 report. The rating was maintained by S&P Research on Wednesday, October 28 with “Hold”. The firm earned “Neutral” rating on Wednesday, October 31 by Credit Suisse. The stock has “Hold” rating by Jefferies on Monday, February 26. The firm has “Buy” rating by Piper Jaffray given on Thursday, September 14. The rating was upgraded by Morgan Stanley on Friday, October 2 to “Overweight”.

Since July 20, 2018, it had 0 buys, and 2 insider sales for $1.92 million activity. On Monday, August 13 the insider OLSON LAURIE J sold $418,774.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 29 before the open. They expect $0.64 EPS, up 3.23% or $0.02 from last year’s $0.62 per share. PFE’s profit will be $3.70B for 16.53 P/E if the $0.64 EPS becomes a reality. After $0.78 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -17.95% negative EPS growth.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “European advisory group backs Pfizer’s Avastin biosimilar – Seeking Alpha” on December 14, 2018, also Seekingalpha.com with their article: “Pfizer, Merck cancel avelumab study – Seeking Alpha” published on December 21, 2018, Seekingalpha.com published: “Pfizer Inc. (PFE) CEO Albert Bourla Presents at 37th Annual J.P. Morgan Healthcare Conference (Transcript) – Seeking Alpha” on January 08, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Streetinsider.com and their article: “Pfizer (PFE) Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Discontinued Due to Futility – StreetInsider.com” published on December 20, 2018 as well as Streetinsider.com‘s news article titled: “Pfizer (PFE) Begins Phase 2b/3 Clinical Trial for PF-06651600 for Treatment of Patients with Moderate to Severe Alopecia Areata – StreetInsider.com” with publication date: January 03, 2019.

Chevron Corporation (NYSE:CVX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.